DESIGNING AND IMPLEMENTING OUTCOME-BASED REIMBURSEMENT SCHEMES- EXPERIENCE FROM HUNGARY

Author(s)

Dankó D, Molnár MP, Berta GNational Health Insurance Fund Administration (OEP), Budapest, Hungary

ORGANIZATION: The National Health Insurance Fund Administration (NHIFA) is the competent authority for pharmaceutical pricing and reimbursement in Hungary’s single-insurer health provision system. As a payer, NHIFA is committed to continuous innovation and has promoted an array of novel reimbursement techniques in recent years.  PROBLEM OR ISSUE ADDRESSED: Pharmaceutical cost containment efforts in Hungary were traditionally geared towards generic referencing and statutory payback. Over the recent three years, effective measures have been taken to stabilize annual public pharmaceutical spending at a sustainable level of 1bn EUR (1% of GDP). However, the current worldwide economic crisis, coupled with the intrinsic problems of the Hungarian economy, require that further steps be taken to curb unnecessary expenditures and to liberate resources that can be re-cycled for innovative therapies. With generic referencing losing its momentum, NHIFA is compelled to take a paradigm shift and apply a multi-faceted reimbursement ‘toolkit’ which comprises international referencing, special schemes for biosimilars, compliance programmes and outcome-based reimbursement schemes. These elements represent a growing emphasis on value-based purchasing and are designed to ensure the efficient re-allocation of approx. 10% of the pharmaceutical budget each year. GOALS: Outcome-based reimbursement schemes are aimed at optimizing public spending on active substances newly approved for the formulary. They are based on the insight that real-life therapeutic effectiveness may considerably fall behind efficacy reached in controlled settings. In such schemes, which have a dominant risk-sharing character, NHIFA and the marketing authorisation holder (MAH) enter into a contractual agreement that requires the MAH to pay back a pre-determined amount if the product fails to deliver the outcome ratio on which its dossier has been based and its cost-efficiency has been positively evaluated. OUTCOMES ITEMS USED IN THE DECISION: The therapeutic effectiveness of a product is always measured against the outcome which the MAH refers to as clinical evidence in the reimbursement dossier. IMPLEMENTATION STRATEGY: Outcome-based schemes are linked to price-volume agreements and are now being launched for some high-cost cardiovascular, psychiatry and oncology therapies. As their implementation is currently underway for 8 different products, several methodological issues are currently arising, the analysis of which leads to valuable lessons learned as well as some generalizable conclusions. RESULTS: We confirm international experiences that most challenges related to the design and implementation of outcome-based schemes come down to the feasibility of measuring outcomes and determining the direct and indirect costs of the product not reaching these outcomes (i.e. the expected payback). We have encountered three layers of difficulties: firstly, unlike pharmaceutical reimbursement information, epidemiological data and general health outcome indicators are not satisfactorily collected in Hungary, which renders it unlikely that such databases could be used for the outcome measurement of individual products. Secondly, financing (DRG) data for hospital and outpatient care, through which indirect costs can be assessed, are heavily subject to profit-maximizing coding practices, which induces a number of necessary controls and adjustments before such information can be used in outcome-based schemes. Thirdly, unless pragmatic simplifications are carried out, the administrative costs of these schemes may soar and ultimately outrun the inherent savings potential. In general, we infer that outcome-based schemes are either theoretically exact but impracticable or admittedly stochastic but implementable for products where costs of missing the desired outcome are primarily indirect. Where they are more of a direct nature, the theoretical optimum is considerably easier to approximate. LESSONS LEARNED: We have found that a set of practical simplifications can lead to effective risk-sharing agreements even where exact outcome measurement is impracticable. The ‘heuristic’ approaches we have worked out compromise on the use of surrogate markers to complement ‘hard’ outcome indicators. For some products, re-referral or re-hospitalization with the same cause of illness can serve as a surrogate marker. In other cases, re-referral or re-hospitalization information is only usable if some filters are built in, e.g. only certain wards are considered. Again in other cases, the commencement of a parallel alternative therapy is a clear indicator of the ineffectiveness of the therapy of first choice. It is essential, however, that any ‘heuristic’ should be based on a consensus between the payer and the MAH, elaborated individually for each product so that the agreement will be considered fair by both parties and will not be misused. We recommend that all background information used for outcome (or surrogate marker) measurement should be made publicly accessible and retraceable. We propose that reimbursement may be linked to compliance management programmes wherever outcomes are hard (or costly) to measure but ‘input control’ may result in higher therapeutic effectiveness.

Conference/Value in Health Info

2009-10, ISPOR Europe 2009, Paris, France

Value in Health, Vol. 12, No. 7 (October 2009)

Code

CASE1

Topic

Economic Evaluation, Health Policy & Regulatory

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies, Reimbursement & Access Policy

Disease

Multiple Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×